Left Ventricular Hypertrophy clinical trials at University of California Health
3 in progress, 0 open to eligible people
Gene Therapy Study of RP-A501 in Male Patients With Danon Disease
Sorry, in progress, not accepting new patients
This is a single arm Phase 2 trial to evaluate the efficacy and safety of RP-A501, a recombinant adeno-associated virus serotype 9 (AAV9) containing the human lysosome-associated membrane protein 2 isoform B (LAMP2B) transgene, in male patients with Danon Disease.
at UCSD
Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
Sorry, not currently recruiting here
This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by chance. The study will last for about 60 weeks.
at UCLA UCSD UCSF
Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease
Sorry, in progress, not accepting new patients
This is an 18-month, multicenter, randomized, active-control, parallel-group Phase 3 study, in which participants will be randomized to venglustat versus standard of care therapy (agalsidase alfa, agalsidase beta, or migalastat) to evaluate the effect of venglustat on left ventricular mass index (LVMI) in adult participants with Fabry disease and left ventricular hypertrophy. - Study visits will take place approximately every 3 to 6 months - Participants who complete the randomized period may continue to the long-term extension (LTE) to receive venglustat for up to additional 45 months with the total study duration up to 5.3 years maximum.
at UCLA
Our lead scientists for Left Ventricular Hypertrophy research studies include Barry Greenberg, MD.
Last updated: